GlobeNewswire: Gradalis, Inc. Contains the last 10 of 29 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:10:30ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/04/2804387/0/en/Gradalis-GRAD1405-bi-shRNAi-Candidate-First-to-Show-Positive-Impact-on-Three-Key-KRAS-Mutations-Identified-in-Drug-Resistant-Lung-Colon-and-Pancreatic-Cancers.html?f=22&fvtc=4&fvtv=22027Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers2024-01-04T22:25:28Z<![CDATA[DALLAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control. GRAD1405 is a single agent that has demonstrated the ability to consistently reduce three KRAS mutant proteins: KRAS G12C, G12D and G12V, which are responsible for the rapid resistance to existing therapies and a resulting loss of efficacy. This approach may eliminate the need for multiple therapeutic compounds to address the different genes. Additionally, a precursor of GRAD1405 tested in a pancreatic cancer animal model showed improved benefit, suppression of tumor growth beyond 30 days and no evidence of resistance, over existing therapies. GRAD1405 achieves the silencing of specific genes using Gradalis’ proprietary bi-shRNAi technology, which has consistently reduced targeted genes in clinical trials in multiple cancer indications.]]>https://www.globenewswire.com/news-release/2023/12/05/2790847/0/en/Gradalis-Highlights-Importance-of-Targeting-Clonal-Neoantigens-in-Achieving-Durable-Benefit-in-Cancer-Treatment.html?f=22&fvtc=4&fvtv=22027Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment2023-12-05T13:00:00Z<![CDATA[DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing a personalized anti-cancer therapy for patients with ovarian and other cancers, announced a peer-reviewed publication in Cancers, highlighting the newly discovered critical clinical role of clonal neoantigens in the durable efficacy of immunotherapies in oncology and the potential to use clonal neoantigens as a new biomarker to better identify patients who will best respond to certain immunotherapies. The publication, entitled “Clonal Neoantigen: Emerging ‘Mechanism Based’ Biomarker of Immunotherapy Response”, provides insight into the science and implications of this key discovery. It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens. This may also explain why clonal neoantigen targeting immunotherapies like Gradalis’ Vigil have shown longer-term overall survival benefits in a randomized controlled trial of patients with solid tumors. The full text of the article can be found here.]]>https://www.globenewswire.com/news-release/2023/11/16/2782211/0/en/Gradalis-Awarded-9-9-Million-Grant-From-the-Cancer-Prevention-and-Research-Institute-of-Texas.html?f=22&fvtc=4&fvtv=22027Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas2023-11-16T20:12:08Z<![CDATA[DALLAS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funds will be used to support the company's Phase 2 clinical study of Vigil® in platinum-sensitive patients who have recurrent ovarian cancer with a homologous recombination proficient (HRP) molecular profile. These patients face an acutely high unmet medical need due to the removal of PARP inhibitor therapies in 2022. The study is designed as a pivotal trial to confirm the positive survival results seen in ovarian cancer patients with the HRP profile tumors in Gradalis’ earlier VITAL study in frontline maintenance therapy. The company intends to pursue accelerated approval based on positive results.]]>https://www.globenewswire.com/news-release/2023/10/18/2762277/0/en/Gradalis-to-Host-Virtual-KOL-Discussion-on-the-Vigil-Platform-Entering-Phase-2-for-Platinum-Sensitive-Recurrent-Ovarian-Cancer-on-October-25-2023.html?f=22&fvtc=4&fvtv=22027Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 20232023-10-18T12:00:00Z<![CDATA[DALLAS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer on Wednesday, October 25, 2023 at 11:00am ET. To register for the event, click here.]]>https://www.globenewswire.com/news-release/2023/09/28/2751181/0/en/Gradalis-Highlights-Importance-of-Clonal-Neoantigen-Targeting-for-Clinical-Benefit-of-Vigil-in-Oncology-Reviews-Publication.html?f=22&fvtc=4&fvtv=22027Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication2023-09-28T12:00:00Z<![CDATA[DALLAS, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc. announced the peer-reviewed publication in Oncology Reviews, a Frontiers Open Access Journal, highlighting Vigil activity in ovarian cancer related to clonal neoantigen expression and the HRP molecular profile. Vigil is a personalized immunotherapy that has been tested in multiple studies in ovarian and other cancer tumor types. The publication entitled, “Rationale of Homologous Recombination Proficient Molecular Profile as Biomarker for Therapeutic Targeting in Ovarian Cancer,” provides further insight into why HRP positive ovarian cancer patients are more likely to respond to Vigil immunotherapy. The full text of the article can be found here.]]>https://www.globenewswire.com/news-release/2023/09/21/2747280/0/en/Gradalis-to-Participate-in-the-Cantor-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=22027Gradalis to Participate in the Cantor Global Healthcare Conference2023-09-21T12:30:00Z<![CDATA[DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, clinical stage biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and other cancer tumor types, today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Cantor Global Healthcare Conference, being held in New York, NY from September 26-28, 2023.]]>https://www.globenewswire.com/news-release/2023/06/06/2683308/0/en/Gradalis-Announces-Peer-Reviewed-Publication-Demonstrating-Potential-of-Novel-3D-Scaffold-Tissue-Technology-to-Expand-Vigil-Platform.html?f=22&fvtc=4&fvtv=22027Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform2023-06-06T20:05:00Z<![CDATA[DALLAS, June 06, 2023 (GLOBE NEWSWIRE) -- Gradalis Inc. announced the peer-reviewed publication in Advanced NanoBioMed, highlighting the therapeutic applications of a new extracellular matrix platform developed for tumor cell expansion in collaboration with the University of Michigan Biointerfaces Institute. The publication entitled, “A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells,” provides proof of principle for a large-scale three-dimensional (3D) platform that is designed for high throughput cell proliferation with clinical applications and potential use for Vigil product construction.]]>https://www.globenewswire.com/news-release/2023/03/29/2637133/0/en/Gradalis-to-Participate-in-the-Cantor-Fitzgerald-Future-of-Oncology-Symposium.html?f=22&fvtc=4&fvtv=22027Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium2023-03-29T20:05:00Z<![CDATA[DALLAS, March 29, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and other cancer tumor types, today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.]]>https://www.globenewswire.com/news-release/2023/03/14/2626549/0/en/Gradalis-Announces-Publication-in-Clinical-Cancer-Research-Featuring-Positive-Results-from-a-Study-Evaluating-Vigil-in-Combination-Therapy-for-Patients-with-Recurrent-Ewing-s-Sarco.html?f=22&fvtc=4&fvtv=22027Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's Sarcoma2023-03-14T12:00:00Z<![CDATA[-Pilot study in Ewing's Sarcoma supports the therapeutic potential of Vigil in multiple solid tumor types-]]>https://www.globenewswire.com/news-release/2023/02/02/2600425/0/en/Gradalis-to-Present-at-the-2023-BIO-CEO-Investor-Conference.html?f=22&fvtc=4&fvtv=22027Gradalis to Present at the 2023 BIO CEO & Investor Conference2023-02-02T13:01:00Z<![CDATA[DALLAS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and other cancer tumor types, today announced that Steven Engle, Chief Executive Officer, will provide a corporate update at the BIO CEO & Investor Conference being held both virtually and in New York, NY on February 6-9, 2023.]]>